Advertisement
Survey Series
Institutions
For Advertisers
|
|
||||
|
Ariad licenses prized pathway
Email: Peg Brickley - pegbrickley@hotmail.com News from The Scientist 2003, 4(1):20030513-01
|
||||
|
|
||||
|
Ariad Pharmaceuticals has signed its second license deal for the NF-κB patent, which covers a heavily researched protein signaling pathway believed to be a key to cancer, osteoporosis, and inflammatory diseases. Reagent maker DiscoveRx signed up for a nonexclusive worldwide license of rights under the patent, granted last summer to the Whitehead Institute of Biomedical Research, Harvard University, and Massachusetts Institute of Technology, and licensed by Ariad, a Cambridge, Mass. biotech.
|
|
|||||||||
|
|||||||||
|
